From: Predicting responsiveness to GLP-1 pathway drugs using real-world data
Features | Number of subjects | Decrease in HbA1c (mean ± SD) | False Discovery Rate (FDR) | |
---|---|---|---|---|
Sex | Female | 3911 | 0.45 ± 1.48 | 3.09E-02 |
Male | 3945 | 0.55 ± 1.64 | ||
Hispanic ethnicity | No | 7635 | 0.50 ± 1.56 | 2.39E-01 |
Yes | 221 | 0.46 ± 1.58 | ||
Race | Africa American | 1386 | 0.55 ± 1.83 | 8.91E-02 |
Non-African American | 6470 | 0.48 ± 1.50 | ||
White | 6193 | 0.49 ± 1.51 | 1.56E-01 | |
Non-White | 1663 | 0.53 ± 1.75 | ||
Asian | 149 | 0.19 ± 1.08 | 1.06E-02 | |
Non-Asian | 7707 | 0.50 ± 1.58 | ||
Other | 147 | 0.61 ± 1.34 | 9.96E-02 | |
Non-Other | 7709 | 0.49 ± 1.57 | ||
Chronic kidney disease | Yes | 1069 | 0.32 ± 1.50 | 6.65E-04 |
No | 6787 | 0.53 ± 1.58 | ||
Cardiomyopathy | Yes | 341 | 0.32 ± 1.44 | 3.19E-02 |
No | 7515 | 0.51 ± 1.57 | ||
Heart failure | Yes | 654 | 0.33 ± 1.51 | 4.58E-03 |
No | 7202 | 0.51 ± 1.57 | ||
Hypertension | Yes | 5566 | 0.51 ± 1.51 | 3.59E-03 |
No | 2290 | 0.47 ± 1.69 | ||
Arthritis | Yes | 1447 | 0.45 ± 1.36 | 2.30E-01 |
No | 6409 | 0.51 ± 1.61 | ||
Gastric bypass | Yes | 148 | 0.64 ± 1.49 | 5.61E-02 |
No | 7708 | 0.49 ± 1.57 | ||
Bowel resection | Yes | 82 | 0.25 ± 1.55 | 2.23E-01 |
No | 7774 | 0.50 ± 1.57 | ||
Retinopathy | Yes | 333 | 0.28 ± 1.49 | 3.96E-02 |
No | 7523 | 0.51 ± 1.57 | ||
Insulin | Yes | 2031 | 0.66 ± 1.81 | < 1.0E-100 |
No | 5825 | 0.44 ± 1.47 | ||
Metformin | Yes | 4734 | 0.54 ± 1.59 | 1.78E-08 |
No | 3122 | 0.43 ± 1.52 | ||
Sulfonylureas | Yes | 3041 | 0.49 ± 1.58 | 5.16E-03 |
No | 4815 | 0.50 ± 1.56 | ||
Thiazolidinediones | Yes | 773 | 0.37 ± 1.53 | 3.29E-01 |
No | 7083 | 0.51 ± 1.57 | ||
NSAIDs | Yes | 3966 | 0.46 ± 1.53 | 5.16E-03 |
No | 3890 | 0.54 ± 1.60 | ||
Painkiller | Yes | 1542 | 0.43 ± 1.56 | 6.76E-03 |
No | 6314 | 0.51 ± 1.57 | ||
Other T2D Medication | Yes | 488 | 0.49 ± 1.38 | 6.08E-02 |
No | 7368 | 0.50 ± 1.58 | ||
Smoking | Yes | 2888 | 0.53 ± 1.59 | 2.82E-01 |
No | 4968 | 0.48 ± 1.55 |